GlassScriptPhysician profile
Timara L Stelling
NPI 1235595240
$7,759.05
in general payments reported to CMS, 2019-2025
36 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,047 · 2022: $1,312 · 2023: $1,573 · 2024: $1,848 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,334 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,334.43 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $973.25 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $864.26 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $853.79 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $796.87 | 2021-2025 | |
| Abbvie INC. | $620.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $459.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $413.52 | 2021-2025 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $391.67 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.58 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $347.62 | 2021-2023 | |
| Astellas Pharma US INC | $263.86 | 2022-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $186.60 | 2021-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $149.34 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.43 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $118.26 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $115.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $108.90 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $89.61 | 2022-2025 | Austedo Xr, Austedo Xr |
| Mylan Specialty L.P. | $63.53 | 2022-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $55.78 | 2023 | Nuedexta |
| Halozyme INC | $37.65 | 2023 | |
| Sunovion Pharmaceuticals INC. | $36.79 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.13 | 2024 | Voquezna |
| Viatris Specialty LLC | $33.04 | 2025 | Yupelri |
| Mayne Pharma Commercial LLC | $27.92 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $27.90 | 2023 | |
| Boston Scientific Corporation | $22.99 | 2024 | Wavewriter Alpha Prime 16 |
| Edwards Lifesciences Corporation | $22.65 | 2024 | |
| Lundbeck LLC | $18.00 | 2024 | Rexulti |
| Genentech USA, INC. | $17.70 | 2021 | |
| Radius Health, INC. | $17.63 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.99 | 2021 | |
| Dexcom, INC. | $15.47 | 2023 | Dexcom G6 Transmitter |
| Alvogen INC | $15.37 | 2022 | |
| Biogen, INC. | $15.31 | 2025 | Skyclarys |
| Currax Pharmaceuticals LLC | $13.22 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timara Stelling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.